Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors

Inflammatory Bowel Diseases

Volumn 18, Issue 6, 2012, Pages 1137-1145

  Fichna, Jakub ^a,c   Dicay, Michael ^b   Lewellyn, Kevin ^d   Janecka, Anna ^c   Zjawiony, Jordan K ^d   MacNaughton, Wallace K ^b   Storr, Martin A ^a,e  

^a UNIVERSITY OF CALGARY   (Canada)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF MISSISSIPPI   (United States)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

cannabinoid receptors; inflammatory bowel disease; kappa opioid receptor; salvinorin A

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALLYL ISOTHIOCYANATE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DEXTRAN SULFATE; KAPPA OPIATE RECEPTOR; MYELOPEROXIDASE; NORBINALTORPHIMINE; SALVINORIN A; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BEHAVIOR; COLITIS; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; MOUSE; NONHUMAN; PAIN; PRIORITY JOURNAL; WESTERN BLOTTING;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS; BLOTTING, WESTERN; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; DITERPENES, CLERODANE; GASTROINTESTINAL MOTILITY; MALE; MICE; NALTREXONE; PAIN; PEROXIDASE; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; RECEPTORS, OPIOID, KAPPA; SALVIA; TRINITROBENZENESULFONIC ACID;

EID: 84861334183     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21873     Document Type: Article

References (40)

1. Satoh M, Minami M,. Molecular pharmacology of the opioid receptors. Pharmacol Ther. 1995; 68: 343-364.
2. Minami M, Satoh M,. Molecular biology of the opioid receptors: structures, functions and distributions. Neurosci Res. 1995; 23: 121-145.
3. Bagnol D, Mansour A, Akil H, et al. Cellular localization and distribution of the cloned mu and kappa opioid receptors in rat gastrointestinal tract. Neuroscience. 1997; 81: 579-591.
4. Fickel J, Bagnol D, Watson SJ, et al. Opioid receptor expression in the rat gastrointestinal tract: a quantitative study with comparison to the brain. Brain Res Mol Brain Res. 1997; 46: 1-8.
5. Pol O, Alameda F, Puig MM,. Inflammation enhances mu-opioid receptor transcription and expression in mice intestine. Mol Pharmacol. 2001; 60: 894-899.
6. Pol O, Palacio JR, Puig MM,. The expression of delta- and kappa-opioid receptor is enhanced during intestinal inflammation in mice. J Pharmacol Exp Ther. 2003; 306: 455-462.
7. Jimenez N, Puig MM, Pol O,. Antiexudative effects of opioids and expression of kappa- and delta-opioid receptors during intestinal inflammation in mice: involvement of nitric oxide. J Pharmacol Exp Ther. 2006; 316: 261-270.
8. Lang ME, Davison JS, Bates SL, et al. Opioid receptors on guinea-pig intestinal crypt epithelial cells. J Physiol. 1996; 497 (Pt 1): 161-174.
9. Snape WJ Jr, Matarazzo SA, Cohen S,. Abnormal gastrocolonic response in patients with ulcerative colitis. Gut. 1980; 21: 392-396.
10. Spriggs EA, Code CF, Bargen JA, et al. Motility of the pelvic colon and rectum of normal persons and patients with ulcerative colitis. Gastroenterology. 1951; 19: 480-491.
11. Harada Y, Nishioka K, Kitahata LM, et al. Contrasting actions of intrathecal U50,488H, morphine, or [D-Pen2, D-Pen5] enkephalin or intravenous U50,488H on the visceromotor response to colorectal distension in the rat. Anesthesiology. 1995; 83: 336-343.
12. Danzebrink RM, Green SA, Gebhart GF,. Spinal mu and delta, but not kappa, opioid-receptor agonists attenuate responses to noxious colorectal distension in the rat. Pain. 1995; 63: 39-47.
13. Diop L, Riviere PJ, Pascaud X, et al. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. Eur J Pharmacol. 1994; 271: 65-71.
14. Stein C, Clark JD, Oh U, et al. Peripheral mechanisms of pain and analgesia. Brain Res Rev. 2009; 60: 90-113.
15. Sengupta JN, Snider A, Su X, et al. Effects of kappa opioids in the inflamed rat colon. Pain. 1999; 79: 175-185.
16. Burton MB, Gebhart GF,. Effects of kappa-opioid receptor agonists on responses to colorectal distension in rats with and without acute colonic inflammation. J Pharmacol Exp Ther. 1998; 285: 707-715.
17. Fichna J, Schicho R, Andrews CN, et al. Salvinorin A inhibits colonic transit and neurogenic ion transport in mice by activating kappa-opioid and cannabinoid receptors. Neurogastroenterol Motil. 2009; 21: 1326-e1328.
18. Capasso R, Borrelli F, Capasso F, et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A inhibit enteric cholinergic transmission in the guinea-pig ileum. Neurogastroenterol Motil. 2006; 18: 69-75.
19. Storr MA, Keenan CM, Zhang H, et al. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis. 2009; 15: 1678-1685.
20. Laird JM, Martinez-Caro L, Garcia-Nicas E, et al. A new model of visceral pain and referred hyperalgesia in the mouse. Pain. 2001; 92: 335-342.
21. Eijkelkamp N, Kavelaars A, Elsenbruch S, et al. Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: spinal cord c-Fos expression and behavior. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G749-G757.
22. Walker JS,. Anti-inflammatory effects of opioids. Adv Exp Med Biol. 2003; 521: 148-160.
23. Camilleri M,. Novel pharmacology: asimadoline, a kappa-opioid agonist, and visceral sensation. Neurogastroenterol Motil. 2008; 20: 971-979.
24. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004; 113: 1202-1209.
25. Roth BL, Baner K, Westkaemper R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A. 2002; 99: 11934-11939.
26. Capasso R, Borrelli F, Cascio MG, et al. Inhibitory effect of salvinorin A, from Salvia divinorum, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. Br J Pharmacol. 2008; 155: 681-689.
27. Lawrence DM, el-Hamouly W, Archer S, et al. Identification of kappa opioid receptors in the immune system by indirect immunofluorescence. Proc Natl Acad Sci U S A. 1995; 92: 1062-1066.
28. Sharp BM, Roy S, Bidlack JM,. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol. 1998; 83: 45-56.
29. Ignatowski TA, Bidlack JM,. Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther. 1998; 284: 298-306.
30. Galiegue S, Mary S, Marchand J, et al. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 1995; 232: 54-61.
31. Chuang LF, Chuang TK, Killam KF Jr, et al. Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem Biophys Res Commun. 1995; 209: 1003-1010.
32. Gaveriaux C, Peluso J, Simonin F, et al. Identification of kappa- and delta-opioid receptor transcripts in immune cells. FEBS Lett. 1995; 369: 272-276.
33. Alicea C, Belkowski SM, Sliker JK, et al. Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages. J Neuroimmunol. 1998; 91: 55-62.
34. Carr DJ,. The role of endogenous opioids and their receptors in the immune system. Proc Soc Exp Biol Med. 1991; 198: 710-720.
35. Eisenstein TK, Hilburger ME,. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J Neuroimmunol. 1998; 83: 36-44.
36. Aviello G, Borrelli F, Guida F, et al. Ultrapotent effects of salvinorin A, a hallucinogenic compound from Salvia divinorum, on LPS-stimulated murine macrophages and its anti-inflammatory action in vivo. J Mol Med. 2011; 89: 891-902.
37. Capasso R, Borrelli F, Zjawiony J, et al. The hallucinogenic herb Salvia divinorum and its active ingredient salvinorin A reduce inflammation-induced hypermotility in mice. Neurogastroenterol Motil. 2008; 20: 142-148.
38. Fichna J, Schicho R, Janecka A, et al. Selective natural kappa opioid and cannabinoid receptor agonists with a potential role in the treatment of gastrointestinal dysfunction. Drug News Perspect. 2009; 22: 383-392.
39. Leighton GE, Rodriguez RE, Hill RG, et al. kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol. 1988; 93: 553-560.
40. Stevens CW, Yaksh TL,. Dynorphin A and related peptides administered intrathecally in the rat: a search for putative kappa opiate receptor activity. J Pharmacol Exp Ther. 1986; 238: 833-838.